Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

This trial is studying a combination of three drugs — venetoclax, lenalidomide, and rituximab — as a first treatment for mantle cell lymphoma, a type of blood cancer, to see if this combination can produce longer-lasting remissions without the need for stem cell transplant. **You may be eligible if...** - You are 18 years or older - You have been newly diagnosed with mantle cell lymphoma (confirmed by biopsy) - You have not received any prior chemotherapy or antibody treatments for mantle cell lymphoma - Your general health allows you to be somewhat active (ECOG score 0–2) - You are willing and able to participate in a mandatory drug safety monitoring program (called Revlimid REMS) - You can swallow oral capsules and tablets - You are using appropriate contraception if you are of childbearing age **You may NOT be eligible if...** - You have already been treated with chemotherapy for mantle cell lymphoma - You are pregnant or breastfeeding - You have significant nerve damage (grade 2 or higher), heart disease, or an active infection - The cancer has spread to the brain or spinal fluid - You have a condition that prevents proper absorption of oral medications Talk to your doctor to see if this trial is right for you.